Scrutiny Made to SUPAC-IR Dealing with Postapproval Changes in Immediate Release Sold Oral Dosage Forms |
Sah, Hong-Kee
(College of Pharmacy, Catholic University of Daegu)
Park, Sang-Ae (Korea Food & Drug Administration) Yun, Mi-Ok (Korea Food & Drug Administration) Kang, Shin-Jung (Korea Food & Drug Administration) |
1 | J.P. Skelly, G.A. Van Buskirk, DR Savello, G.L. Amidon and et ai., Scale-up and immediate release oral solid dosage forms,.Phann. Res., 10, 313-16 (1993) DOI |
2 | FDA, Federal Register, 59, 48754-48759 (1994) |
3 | FDA, Center for Drug Evaluation and Research, SUPAC-IR questions and answers to SUPAC-IR guidance, February 1997 |
4 | FDA, Center for Drug Evaluation and Research, Guidance for Industry: SUPAC-IRIMR: Immediate release and modified release solid oral dosage forms; Manufacturing equipment addendum, January 1999 |
5 | 일본국립의약식품위생연구소(National Institute of Health Sciences), Division of Drugs, Guideline for bioequivalence studies for formulation changes of oral solid forms, February 2000 |
6 | 식품의약품안전청고시 제 2002-60호 '생물학적동등성시험 기준' 제 3조 제 4항 |
7 | 식품의약품안전청고시 제 2002-60호 '생물학적동등성시험 기준' 제 3조 제 5항 |
8 | M. Cho, J Kim, H. Lee and H. Sah, Understanding of f mettics used to evaluate similarity of dissolution profiles, J. Kor. Pharm. Sci., 33, 245-253 (2003) |
9 | FDA, Department of Health and Human Services, Supplements and other changes to an approved application, Federal Register, 64, 34608-34625 (1999) |
10 | FDA, Center of Drug Evaluation and Research, Guidance for Industry-Changes to an approved NDA or ANDA, November 1999 |
11 | FDA, Center for Drug Evaluation and Research, Guidance for Industry-Immediate release solid oral dosage forms: Scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, November 1995 |
12 | FDA, Center for Drug Evaluation and Research, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August 2000 |
13 | J.A. Cook, Industrial experience with the BCS guidance in NDA: Value and limitations, AAPS Workshop on Biopharmaceutics Classification System: Implementation Challenges and Extension Opprotunities, Arlington, VA, September 2002 |
14 | FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research & Center for Veterinary Medicine, Guidance for Industry: Comparability protocolschemisty, manufacturing, and controls information, February 2003 |